MapLight Therapeutics, Inc. · Conversion · Voting Common Stock

What does this filing report?

An SEC Form 4 filing for MapLight Therapeutics, Inc. records a conversion involving Voting Common Stock on October 28, 2025. The reported quantity was 14,256,288. The filing date is October 29, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

The Series A, A-1, B, B-1, C and D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F2

The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

F3

The Series A Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F4

The Series A-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F5

The Series B Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date.

F6

The Series B-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F7

The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F8

The Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.